glp 1 gut hormone GLP-1 and Microbiome Repair for Long-Term Metabolism A surprising role for enteroendocrine

Description

Safety concerns were also raised in a phase 1 trial investigating the GLP-1R/GCGR agonist NNC9204-117, where a dose-dependent increase in heart rate was observed, in addition to increased markers of inflammation, hepatic disturbances, impaired glucose tolerance, and reduced blood levels of some amino acids despite clinically relevant weight loss (Friedrichsen et al

Compounded Medications Compounded medications are prepared by licensed pharmacies based on individual prescriptions

For type 2 diabetes management , NICE guideline NG28 recommends considering GLP-1 receptor agonists when: Triple therapy with metformin and two other oral medications is ineffective, not tolerated or contraindicated The patient has a body mass index (BMI) of 35 kg/m or higher (with lower thresholds for people from certain ethnic backgrounds), or lower BMI with specific clinical circumstances where weight loss would benefit other obesity-related comorbidities Insulin would have significant occupational implications GLP-1 therapy should only be continued beyond six months if there has been a beneficial metabolic response, defined as a reduction in HbA1c of at least 11 mmol/mol (1.0 percentage point) and weight loss of at least 3% of initial body weight

Goldman, MD Medical Reviewer Anna L

98,99 Given that GLP-1RA is a significant moderator of the gut-brain axis, it could potentially impact the brain indirectly through vagal nerve fibers in the enteric region, conveying metabolic information to NTS